acetylcarnitine has been researched along with Neoplasms in 5 studies
Acetylcarnitine: An acetic acid ester of CARNITINE that facilitates movement of ACETYL COA into the matrices of mammalian MITOCHONDRIA during the oxidation of FATTY ACIDS.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ifosfamide and cisplatin cause urinary loss of carnitine, which is a fundamental molecule for energy production in mammalian cells." | 6.70 | Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. ( Baldelli, AM; Bisonni, R; Canestrari, F; Catalano, V; De Gaetano, A; Ferraro, B; Giordani, P; Graziano, F; Lai, V; Mencarini, E; Rovidati, S; Silva, R; Testa, E, 2002) |
| "Fatigue was assessed by the Functional Assessment of Cancer Therapy-Fatigue quality of life questionnaire." | 6.70 | Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. ( Baldelli, AM; Bisonni, R; Canestrari, F; Catalano, V; De Gaetano, A; Ferraro, B; Giordani, P; Graziano, F; Lai, V; Mencarini, E; Rovidati, S; Silva, R; Testa, E, 2002) |
| "To evaluate the effect of the anti-cancer drug carboplatin on plasma concentrations and urinary excretion of L-carnitine (LC) and its main ester, acetyl-L-carnitine (ALC), in cancer patients." | 2.73 | Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ( Bisonni, R; Calvani, M; D'Iddio, S; Graziano, F; Lippe, P; Mancinelli, A, 2007) |
| "Ifosfamide and cisplatin cause urinary loss of carnitine, which is a fundamental molecule for energy production in mammalian cells." | 2.70 | Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. ( Baldelli, AM; Bisonni, R; Canestrari, F; Catalano, V; De Gaetano, A; Ferraro, B; Giordani, P; Graziano, F; Lai, V; Mencarini, E; Rovidati, S; Silva, R; Testa, E, 2002) |
| "Fatigue was assessed by the Functional Assessment of Cancer Therapy-Fatigue quality of life questionnaire." | 2.70 | Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. ( Baldelli, AM; Bisonni, R; Canestrari, F; Catalano, V; De Gaetano, A; Ferraro, B; Giordani, P; Graziano, F; Lai, V; Mencarini, E; Rovidati, S; Silva, R; Testa, E, 2002) |
| "CIPN is an important consequence of cancer treatment because of its potential impact on physical functioning and quality of life." | 2.44 | Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy. ( Abbott, L; Aschenbrenner, J; Collins, M; Hart, C; Visovsky, C, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zahednezhad, F | 1 |
| Shahbazi Mojarrad, J | 1 |
| Zakeri-Milani, P | 1 |
| Baradaran, B | 1 |
| Mahmoudian, M | 1 |
| Sarfraz, M | 1 |
| Valizadeh, H | 1 |
| van Dam, DG | 1 |
| Beijers, AJ | 1 |
| Vreugdenhil, G | 1 |
| Mancinelli, A | 1 |
| D'Iddio, S | 1 |
| Bisonni, R | 2 |
| Graziano, F | 2 |
| Lippe, P | 1 |
| Calvani, M | 1 |
| Visovsky, C | 1 |
| Collins, M | 1 |
| Abbott, L | 1 |
| Aschenbrenner, J | 1 |
| Hart, C | 1 |
| Catalano, V | 1 |
| Silva, R | 1 |
| Rovidati, S | 1 |
| Mencarini, E | 1 |
| Ferraro, B | 1 |
| Canestrari, F | 1 |
| Baldelli, AM | 1 |
| De Gaetano, A | 1 |
| Giordani, P | 1 |
| Testa, E | 1 |
| Lai, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer[NCT02549534] | 29 participants (Actual) | Observational | 2015-09-30 | Completed | |||
| A Randomised, Double Blinded Cross-over Study Comparing the Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis[NCT01149525] | Phase 3 | 59 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for acetylcarnitine and Neoplasms
| Article | Year |
|---|---|
Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy.
Topics: Acetylcarnitine; Acupuncture Therapy; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineoplas | 2007 |
2 trials available for acetylcarnitine and Neoplasms
| Article | Year |
|---|---|
Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment.
Topics: Acetylcarnitine; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area U | 2007 |
Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients.
Topics: Acetylcarnitine; Aged; Antineoplastic Agents; Carnitine; Cisplatin; Fatigue; Female; Humans; Ifosfam | 2002 |
2 other studies available for acetylcarnitine and Neoplasms
| Article | Year |
|---|---|
Surface modification with cholesteryl acetyl carnitine, a novel cationic agent, elevates cancer cell uptake of the PEGylated liposomes.
Topics: Acetylcarnitine; Cations; Liposomes; Molecular Docking Simulation; Neoplasms; Particle Size; Polyeth | 2021 |
Acetyl-L-carnitine undervalued in the treatment of chemotherapy-induced peripheral neuropathy?
Topics: Acetylcarnitine; Antineoplastic Combined Chemotherapy Protocols; Humans; Neoplasms; Peripheral Nervo | 2016 |